10-K: Azitra Faces Going Concern Amid Rising Losses, NYSE Delisting Threat

Azitra, Inc. reported increased net losses and a significant accumulated deficit for 2025, raising substantial doubt about its ability to continue as a going concern, despite progress in early-stage clinical trials and recent capital raises.

Summary

• Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on precision dermatology using engineered proteins and topical live biotherapeutic products.
• The company reported a net loss of $10.96 million for the year ended December 31, 2025, an increase from $8.97 million in 2024.
• As of December 31, 2025, Azitra had an accumulated deficit of $68.5 million and working capital of $2.0 million.
• Cash and cash equivalents stood at $2.1 million as of December 31, 2025, which management believes is insufficient to cover operations beyond three months from the report date.
• The company received a NYSE American deficiency letter on October 1, 2025, for non-compliance with listing standards due to stockholders' equity below $4.0 million and recurring losses; a compliance plan was accepted on December 16, 2025, with a deadline of April 1, 2027.
• ATR-12, for Netherton syndrome, dosed its first patient in a Phase 1b clinical trial in August 2024 and reported initial safety results in the first half of 2025.
• ATR-04, for EGFRi-associated rash, obtained IND clearance in August 2024, Fast Track designation in September 2024, and dosed its first patient in a Phase 1/2 clinical trial in Q3 2025.
• ATR-01, for ichthyosis vulgaris, completed lead optimization studies in 2025 and continues IND-enabling studies in 2026 for a potential 2026 IND filing.
• The company relies on a proprietary platform including a microbial library of ~1,500 unique bacterial strains, augmented by AI/machine learning and licensed genetic engineering technology (SyMPL from Fred Hutch).
• Azitra has no sales and marketing organization and is completely dependent on third parties for manufacturing product candidates for commercial sale.
• The company holds 7 issued U.S. patents, 2 allowed patent applications, 9 pending U.S. patent applications, and 85 other foreign patents and applications.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly concerning report due to significantly increased losses, a critical 'going concern' warning, and an active NYSE delisting threat, despite some clinical progress and capital raises which appear insufficient for long-term stability.

Positives

• ATR-12 received Pediatric Rare Disease Designation from the FDA in 2019, making it eligible for a Priority Review Voucher upon approval, which can be valuable.
• ATR-12's Phase 1b clinical trial commenced dosing in August 2024, and initial safety results were reported in the first half of 2025, indicating progress in clinical development.
• ATR-04 obtained IND clearance from the FDA in August 2024 and Fast Track designation in September 2024, which could expedite its development and review process.
• ATR-04's Phase 1/2 clinical trial dosed its first patient in Q3 2025, marking advancement for this program.
• The company has a proprietary platform with a microbial library of ~1,500 unique bacterial strains and utilizes AI/machine learning for therapeutic discovery.
• An exclusive worldwide license for SyMPL technology from Fred Hutch expands the ability to genetically modify a broader range of microbial species, potentially enhancing future product candidates.
• The management team has significant experience in biotechnology and healthcare, including co-founders with successful exits in previous ventures.

Negatives

• The company incurred a net loss of $10.96 million in 2025, an increase of 22% from $8.97 million in 2024, indicating worsening financial performance.
• An accumulated deficit of $68.5 million as of December 31, 2025, highlights a history of significant operating losses.
• Cash on hand of $2.1 million as of December 31, 2025, is insufficient to cover the proposed plan of operations beyond three months, raising substantial doubt about the company's ability to continue as a going concern.
• The company received a NYSE American deficiency letter on October 1, 2025, for non-compliance with listing standards, posing a risk of delisting if compliance is not regained by April 1, 2027.
• Service revenue decreased by 100% from $7,500 in 2024 to $0 in 2025, with no expectation of further service revenue.
• The company has no sales and marketing organization and is entirely dependent on third parties for manufacturing commercial products, introducing significant operational and regulatory risks.
• Identified a material weakness in internal control over financial reporting related to a lack of adequate segregation of accounting functions.

Risks

• We are an early-stage clinical biopharmaceutical company with limited operating history and have not commenced revenue-producing operations apart from limited grant and service revenue.
• We have a history of significant operating losses and anticipate continued operating losses for the foreseeable future.
• We expect we will need additional financing to execute our business plan and fund operations, which additional financing may not be available on reasonable terms, or at all.
• The clinical and commercial utility of our microbial library and genetic engineering platform is uncertain and may never be realized.
• Our product candidates are in early stages of development, and therefore they will require extensive additional preclinical and clinical testing.
• We will need to grow the size of our organization, and we may experience difficulties in managing this growth.
• We currently have no sales and marketing organization.
• We will be completely dependent for the foreseeable future on third parties to manufacture our product candidates for commercial sale.
• Our business model includes the potential out-licensing of strains from our proprietary microbial library or our product candidates to other pharmaceutical companies; however, technology licensing in the pharmaceutical industry is a lengthy process and subject to several risks and factors outside of our control.
• Our business may suffer with the loss of key personnel.
• If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
• Our business operations could suffer in the event of information technology systems failures or security breaches.
• We face significant competition from other biotechnology and pharmaceutical companies targeting medical dermatological indications.
• Our success is entirely dependent on our ability to obtain the marketing approval for our product candidates by the FDA and the regulatory authorities in foreign jurisdictions in which we intend to market our product candidates, of which there can be no assurance.
• Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product candidates.
• Results of preclinical studies of our product candidates may not be predictive of the results of future preclinical studies or clinical trials.
• Even if we receive regulatory approval for any of our product candidates, we may not be able to successfully commercialize the product and the revenue that we generate from its sales, if any, may be limited.
• Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
• It is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights.
• Our product candidates may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development and commercialization efforts.
• An active, liquid and orderly trading market for our shares may not develop.
• Future capital raises may dilute your ownership and have other adverse effects on our operations.
• The market price of our shares may be subject to fluctuation and volatility.
• Our failure to meet the continued listing requirements of the NYSE American could result in a delisting of our common stock.
• If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud.
• We ratified certain corporate actions pursuant to Section 204 of the Delaware General Corporate Law, or DGCL; however, there can be no assurance that claims will not be made to challenge the validity of the ratification or the related corporate actions.
• Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.
• Emerging issues related to the development and use of artificial intelligence could give rise to legal or regulatory action, damage our reputation, or otherwise materially harm our business.

Future Outlook

Azitra expects to continue incurring substantial operating losses for the foreseeable future and will require significant additional financing to execute its business plan and fund operations, as current cash on hand is insufficient beyond three months. The company plans to advance its lead programs, ATR-12 and ATR-04, through clinical trials and continue IND-enabling studies for ATR-01. It also intends to explore strategic partnerships and leverage academic collaborations to broaden its platform and pipeline. Management is evaluating the need for a further reverse stock split to address NYSE American compliance.

Management Comments

• Management has determined there is substantial doubt about our ability to continue as a going concern based on our lack of revenue from commercial operations, significant losses, and the need to raise additional capital to support ongoing operations.
• We intend to seek additional funds through various financing sources, including the sale of our equity and debt securities, federal grants, licensing fees for our technology and joint ventures with industry partners.
• We will consider alternatives to our current business plan that may enable us to achieve revenue producing operations and meaningful commercial success with a smaller amount of capital.
• Our Board is still evaluating the need for a further reverse split and, if needed, the exact split ratio based on our financing alternatives and NYSE American compliance considerations.
• We are committed to achieving compliance with the NYSE American's requirements.

Industry Context

StockSavvy.ai notes that Azitra operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically targeting precision dermatology. The company's focus on genetically engineered live biotherapeutic products for conditions like Netherton syndrome and EGFRi-associated rash positions it in a niche with high unmet medical needs but also significant development risks. Competitors in the Netherton syndrome space include Sixera Pharma (SXR-1096) and Quoin Pharmaceuticals (QRX003), both with small molecule inhibitors in clinical trials, and others like ResVita Bio and MatriSys in preclinical stages. For EGFRi-associated rash, competitors include Hoth Therapeutics (HT-001) and Lutris Pharma (LUT014). Azitra's reliance on a novel, unproven therapeutic modality (genetically engineered S. epidermidis) differentiates it but also carries higher inherent risk compared to more established drug classes. The use of AI/machine learning and licensed genetic engineering technologies (SyMPL) could provide a competitive edge in discovery and development, but the commercialization path remains challenging given the capital intensity and regulatory hurdles.

Comparison to Industry Standards

• Azitra's net loss of $10.96 million in 2025, while substantial, is common for early-stage biopharmaceutical companies heavily invested in R&D, similar to many biotech startups prior to commercialization.
• The accumulated deficit of $68.5 million is typical for a company that has been in operation for over a decade without commercial revenue, reflecting the high costs of drug discovery and clinical development.
• The company's cash runway of less than three months is significantly below industry best practices, where biotechs typically aim for 12-18 months of cash on hand to avoid distressed financing situations.
• The NYSE American delisting threat due to low stockholders' equity is a critical concern, indicating a financial position weaker than many publicly traded peers.
• The progress of ATR-12 into Phase 1b and ATR-04 into Phase 1/2 is in line with the typical multi-year development timelines for novel biotherapeutics, though these are still very early stages compared to late-stage clinical assets of more mature biopharma companies.
• The Pediatric Rare Disease Designation for ATR-12 and Fast Track designation for ATR-04 are positive regulatory milestones, comparable to those achieved by other companies developing therapies for serious unmet medical needs, potentially offering expedited review pathways.

Corporate Governance

Related Party Transactions

• Service revenue from a related party (Bayer JDA) decreased from $7,500 in 2024 to $0 in 2025, with no further revenue expected.
• Alumni Capital LP, a single institutional investor, participated in the November 2025 private placement and is the counterparty for the Equity Line of Credit (ELOC). As of February 27, 2026, Alumni Capital LP beneficially owns 9.99% of the company's common stock.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing capital raises, potential loss of investment due to 'going concern' uncertainty, and risk of delisting from NYSE American, which could reduce liquidity and share price.
• **Employees:** The company's financial instability and need for further capital raises could create uncertainty regarding job security and long-term compensation value, despite efforts to attract and retain talent.
• **Customers (Future):** Potential patients for ATR-12, ATR-04, and ATR-01 could benefit from the development of novel therapies for unmet dermatological needs, but the company's financial challenges pose a risk to the successful commercialization and availability of these products.
• **Creditors:** The 'going concern' qualification and accumulated deficit indicate increased risk for current and future creditors.
• **Regulatory Bodies:** The company's compliance with NYSE American listing standards is under review, and its ability to secure and maintain regulatory approvals for its product candidates is critical for its survival.

Next Steps

• Secure additional financing through equity, debt, federal grants, licensing fees, or joint ventures to fund operations beyond the next three months.
• Continue advancing ATR-12 and ATR-04 through their respective clinical trials.
• Complete IND-enabling studies for ATR-01 and potentially file an IND in 2026.
• Implement measures to remediate the material weakness in internal control over financial reporting, including increasing accounting staff and implementing additional review controls.
• Make progress consistent with the plan submitted to NYSE American to regain compliance with listing standards by April 1, 2027, potentially including a further reverse stock split.
• Evaluate and potentially expand academic partnerships to bolster engineering platforms and research and development pipeline.

Key Dates

Recommendation

Azitra faces severe financial distress, evidenced by a substantial increase in net losses, a significant accumulated deficit, and a cash runway of less than three months, leading to a 'going concern' qualification from its auditors. The company is also under threat of delisting from the NYSE American due to non-compliance with listing standards. While there is some clinical progress with early-stage product candidates and recent capital raises, these appear insufficient to address the fundamental financial instability. The high risk of further dilution, potential delisting, and the unproven nature of its therapeutic platform at this early stage make the stock a 'strong sell' for seasoned investors, as the probability of significant capital loss is exceptionally high.

Keywords

Biopharmaceutical, Dermatology, Precision Medicine, Live Biotherapeutic Products, Engineered Proteins, Netherton Syndrome, EGFRi-Associated Rash, Ichthyosis Vulgaris, Staphylococcus epidermidis, Microbiome, Clinical Trials, FDA Approval, Orphan Drug, Fast Track Designation, Genetic Engineering, AI/Machine Learning, SEC Filing, Going Concern, NYSE American Delisting